Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular analysis of renal medullary carcinoma (RMC), a rare and aggressive form of kidney cancer, leading to the identification of TROP2 as a promising therapeutic target.\u00a0<\/p>\n
What is the key discovery in this research and why is it significant?<\/p>\n
By evaluating 25 patient samples, the researchers identified overexpression of TROP2 and several other cell-surface proteins in RMC, as well as upregulation of the Hippo pathway. These findings led to the exploration of sacituzumab govitecan, a TROP2-targeted antibody-drug conjugate.<\/p>\n
In a small cohort of four heavily pretreated RMC patients, sacituzumab govitecan resulted in one partial response and two patients with stable disease, with a median progression-free survival of 2.9 months.<\/p>\n
<\/p>\n
Identifying TROP2 as a therapeutic target in renal medullary carcinoma marks a pivotal step toward precision treatment for one of the most aggressive and underserved cancers.”<\/p>\n
\n
<\/p>\n
Pavlos Msaouel, M.D., Ph.D., principal investigator, associate professor of Genitourinary Medical Oncology<\/p>\n
<\/p>\n
What does this mean for future treatment options?<\/p>\n
Renal medullary carcinoma is a fast-moving, treatment-resistant kidney cancer primarily affecting young individuals with sickle cell trait, highlighting the urgent need to understand its molecular basis to guide therapeutic development.<\/p>\n
This study, which also characterized the RMC tumor microenvironment, supports further investigation of drugs targeting TROP2 as treatment options for this patient population.<\/p>\n
Source:<\/p>\n
University of Texas M. D. Anderson Cancer Center<\/a><\/p>\n Journal reference:<\/p>\n